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Abstract
Background: We conducted multiple microarray datasets analyses from clinical and xenograft tumor tissues to
search for disease progression-driving oncogenes in prostate cancer (PCa). Sperm-associated antigen 5 (SPAG5)
attracted our attention. SPAG5 was recently identified as an oncogene participating in lung cancer and cervical
cancer progression. However, the roles of SPAG5 in PCa progression remain unknown.
Methods: SPAG5 expression level in clinical primary PCa, metastatic PCa, castration resistant PCa, neuroendocrine
PCa, and normal prostate tissues was investigated. We established multiple in vivo xenografts models using patient-
derived tissues and investigated SPAG5 expression trend in these models. We also investigated the functions of
SPAG5 in vivo and in vitro studies. Luciferase reporter assays were performed to investigate potential miRNAs that
can regulate SPAG5.
Results: We identified that SPAG5 expression was gradually increased in PCa progression and its level was significantly
associated with lymph node metastasis, clinical stage, Gleason score, and biochemical recurrence. Our results indicated
that SPAG5 knockdown can drastically inhibit PCa cell proliferation, migration, and invasion in vitro and supress tumor
growth and metastasis in vivo. We identified that miR-539 can directly target SPAG5. Ectopic overexpression of miR-539
can drastically inhibit SPAG5 expression and the restoration of SPAG5 expression can reverse the inhibitory effects of
miR-539 on PCa cell proliferation and metastasis.
Conclusion: Our results collectively showed a progression-driving role of SPAG5 in PCa which can be regulated by
miR-539, suggesting that miR-539/SPAG5 can serve as a potential therapeutic target for PCa.
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Background
Prostate cancer (PCa) is one of the most common and
aggressive human malignancies with poor prognosis
worldwide [1]. Although considerable advances in ther-
apy and diagnosis of PCa have been made, many PCa
patients will progress to castration-resistant PCa (CRPC)
that is metastatic and shows resistance to hormonal
therapy [2]. Neuroendocrine PCa (NEPC) is another
lethal form of PCa with most patients dying within 1 year
of diagnosis despite very aggressive chemotherapeutic
regimens [3]. Increasing evidence indicates that prostatic
adenocarcinoma can undergo a NE transdifferentiation
following long-term androgen deprivation therapy, and
eventually progress to NEPC [3, 4]. However, NEPC
studies have been hampered by a lack of clinically rele-
vant in vivo models of the disease. Recently, our lab suc-
cessfully has generated a patient-derived xenograft
model of complete neuroendocrine transdifferentiation
(LTL331R) of a prostate adenocarcinoma (LTL331) at
the Living Tumor Laboratory [5]. Therefore, NEPC
xenograft model provides a valuable method for investi-
gating the molecular mechanisms of NEPC progression.
So discovery of new optimize therapeutic targets for
more effective treatment of metastatic PCa, CRPC, and
NEPC is urgently needed for improved disease manage-
ment and patient survival [6].
It is well known that sperm-associated antigen 5
(SPAG5) can bind to microtubules as a regulator of the
timing of spindle organization and separation of sister
chromatids [7]. Previous studies indicated that SPAG5
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was an important variable in mitosis and cell cycle
checkpoint regulation [8]. A previous study indicated
that SPAG5 may act as a promoter in tumorigenesis and
progression [9]. Previous studies showed that SPAG5
overexpression can predict poor prognosis in lung can-
cer and cervical cancer [9–11] and alter sensitivity to
taxol treatment via the mTOR signaling pathway in cer-
vical cancer [11]. These results indicated that SPAG5
may act as an important oncogene that is involved in the
formation and progression of malignancies and might
influence the biological behaviors of malignancies. How-
ever, the molecular mechanism and role of SPAG5 in
PCa development and progression have not yet been
investigated.
miRNAs are small noncoding RNAs of ~22 nt that
can regulate gene expression by inhibiting protein trans-
lation and promoting the degradation of the target
mRNAs by binding to the 3’ untranslated regions (UTR)
of specific mRNAs. An expanding body of evidence has
showed that the dysregulation of miRNAs is linked to
the development of various types of cancers [12–16]. In-
creasing evidence indicates a critical role for miRNAs in
cancer initiation, promotion, and progression [17–19].
In view of the extensive functions of miRNAs and
SPAG5, there is an urgent need to identify the molecular
mechanism and role of SPAG5 in PCa progression and
to investigate whether or not SPAG5 can be targeted by
a specific miRNA in PCa.
In the current study, we identified that SPAG5 expres-
sion level is drastically increased in primary PCa relative
to normal samples, metastatic PCa samples relative to pri-
mary PCa, CRPC relative to hormone naïve PCa, and
NEPC relative to prostate adenocarcinoma, respectively.
We also identified that knockdown of SPAG5 significantly
inhibited the proliferation, migration, and invasion in PCa
cells. We further confirmed that miR-539 inhibited the
PCa growth and metastasis in vivo and also inhibited the
proliferation, migration, and invasion in vitro by down-
regulating SPAG5 expression. Taken together, our
research results position SPAG5 as a progression-driving
oncogene in PCa and a potential therapeutic target in
PCa, providing opportunities to explore novel strategies
aimed at reversing PCa progression.
Methods
Tissue samples
One hundred eighty PCa and paired adjacent normal tis-
sues confirmed by pathologists were collected from the
second hospital of Tianjin medical university [20, 21].
We also collected 20 CRPC tissues. Informed consent
was obtained from each patient, and all of the experi-
ments were approved by the ethics committee of the
institute.
PCa cell lines
PC-3 (a cell line characteristic of prostatic small cell
neuroendocrine carcinoma) and LNCaP cell lines were
cultured in RPMI 1640 (Life Technologies, CA) with
0.023 IU/ml insulin and 10 % FBS (Invitrogen) in 5 %
CO2 cell culture incubator.
Plasmid construction
We amplified a DNA fragment containing the pri-miR-
539 gene DNA from genomic human DNA by PCR. This
fragment was then inserted into pcDNA3 vector. The
primers for knocking down SPAG5 were synthesized,
annealed, and cloned into the pSilencer2.1-neo vector.
The SPAG5 cDNA containing the coding sequence was
cloned by PCR, and the PCR product was cloned into
the pcDNA3 vector.
Colony formation assay
We seed the PCa cells on 35-mm dishes according to
the manufacturers’ instructions. The PCa cells were
fixed in methanol, and then stained with crystal accord-
ing to the manufacturers’ instructions. Positive colony
formation (>50 cells/colony) would be counted.
Migration and invasion assays
The transwell migration and invasion assays were con-
ducted with coated Matrigel (invasion) and uncoated
(migration) according to the manufacturers’ instructions.
The migrated and invaded cells in the membrane would
be fixed, stained, and counted.
Luciferase reporter assay
The miR-539-binding site in the SPAG5 3’-UTR region
(wild or mutant-type) was cloned downstream of the
firefly luciferase gene in a pGL3-promoter vector. The
luciferase assay was conducted according to the manu-
facturers’ instructions.
qRT-PCR
Total RNA was extracted using Trizol Reagent according
to the manufacturers’ instructions. The miR-539 expression
was measured by TaqMan miRNA assays according to the
manufacturers’ instructions, U6 was used for normalization.
SPAG5 mRNA expression level was investigated by SYBR
green qPCR assay and β-actin was used as an endogenous
control.
Western blots
Detailed procedure for western blot was performed ac-
cording to the manufacturers’ instructions. In brief, the
interest protein was resolved by SDS-PAGE and trans-
ferred to a PVDF membrane, which was probed with
specific primary antibody against SPAG5 (HPA022479,
Sigma). β-actin was used as the endogenous control.
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Immunohistochemistry
The Immunohistochemistry study was conducted ac-
cording to the manufacturers’ instructions using specific
primary antibody against SPAG5 (HPA022479, Sigma).
The SPAG5 protein would be classified semiquantita-
tively combining the proportion and intensity of posi-
tively stained immunoreactive cells [20, 21]. The sum of
the staining intensity score and the percentage score was
used to define SPAG5 protein level: 0–2, low expression
and 3–4, high expression [20, 21].
PCa xenograft research
The LNCaP and PC-3 cells were stably transfected with
pri-miR-539, control, or SPAG5 knockdown vector. The
Fig. 1 SPAG5 is gradually increased in normal prostate, primary PCa, metastatic PCa, CRPC, and NEPC. a-e, Scatter plots represent SPAG5 mRNA in
normal prostate and primary PCa samples; d-h, and i, Scatter plots represent SPAG5 mRNA in primary PCa and metastatic PCa samples; i, Scatter
plots represent SPAG5 mRNA in metastatic PCa and CRPC samples; j. Scatter plots represent SPAG5 mRNA in prostate adernocarcinoma and
NEPC samples; k, Scatter plots showed that SPAG5 mRNA was upregulated in three NEPC models (LTL331R, LTL352, and LTL370) relative to these
prostate adenocarcinoma models, metastatic (LTL313H) PCa xenograft line relative to non-metastatic (LTL313B) PCa xenograft line, CRPC xenograft
model (313BR) compared with LTL313B; l, Scatter plots showed that SPAG5 was downregulated after host castration and significantly upregulated
in fully relapsed NEPC xenografts
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cells were subcutaneously injected into the 6 week-old
nude mice in the flank. Mouse weight and tumor size
were measured biweekly. The tumor volume was calcu-
lated as follows: length × width2 × 1/2. The xenograft tu-
mors and cervical lymph nodes samples were collected
and tumor weights were measured 7 weeks after im-
plantation. DNA extraction of the cervical lymph nodes
and human alu sequence PCR amplification were
performed to identify the distant metastasis status
according to a previous paper [22].
Statistical analysis
Student’s t-test was conducted for continuous data.
Spearman correlation test was used to investigate the as-
sociations between SPAG5 protein level and the clinical
and pathological factors. Survival curves were conducted
by the Kaplan-Meier and investigated through log-rank
test. Identified variables were associated with survival by
the Cox proportional hazard regression. A p value less
than 0.05 was considered significant. Statistical analysis
was performed by SPSS 17.0.
Results
SPAG5 may be a potential progression-driving oncogene
In order to investigate whether any difference of SPAG5
expression exists in primary PCa, metastatic PCa, CRPC,
NEPC, and normal prostate tissues, several microarray
datasets were analyzed [23–30]. We identified that
SPAG5 mRNA was significantly overexpressed in pri-
mary PCa relative to normal prostate tissues (Fig. 1a-e)
and metastatic PCa compared with primary PCa sam-
ples, respectively (Fig. 1d-h). The microarray data also
showed that SPAG5 mRNA was higher in CRPC samples
than in hormone naïve PCa samples (Fig. 1i). We also
investigated SPAG5 expression in a clinical cohort that
included 30 prostate adenocarcinoma and 7 NEPC
patients. The RNA-seq data of this cohort showed that
SPAG5 was significantly upregulated in NEPC samples
compared with prostate adenocarcinoma samples (Fig. 1j).
In order to validate clinical cohort results, we further inves-
tigate SPAG5 mRNA expression in a panel of patient
tissue-derived PCa xenograft models generated from our
lab. The results indicated that SPAG5 mRNA was upregu-
lated in three NEPC models (LTL331R, LTL352, and
LTL370) relative to these prostate adenocarcinoma models
(Fig. 1k). We also analyzed gene expression profile of paired
metastatic (LTL313H) and non-metastatic (LTL313B) PCa
tissue xenograft lines derived from one patient’s primary
tumor, LTL313H showed higher expression of SPAG5 rela-
tive to LTL313B. Similarly, increased SPAG5 mRNA was
identified in CRPC xenograft model (313BR) compared
with LTL313B (Fig. 1k). Our lab also has analysed the
microarray data from LTL331 xenografts before and after
host castration at various time points. We identified that
SPAG5 was downregulated after host castration and signifi-
cantly upregulated in fully relapsed NEPC xenografts
(Fig. 1l). Collectively, above data indicated that SPAG5 in-
creases gradually during the PCa progression, indicating it
has a very critical role in PCa progression.
SPAG5 is significantly associated with PCa progression
and poor prognosis
We also performed microarray analysis to identify
whether SPAG5 was associated with PCa progression
[30–33]. We identified that high SPAG5 expression was
significantly associated with higher PCa grade, and
higher stage (Fig. 2a-e). SPAG5 expression was signifi-
cantly overexpressed in dead PCa patients compared
with living PCa patients at 3 years and 5 years, respect-
ively (Fig. 2f, g). We also identified that SPAG5 expres-
sion was significantly increased in PCa patients with
BCR compared with PCa patients without BCR at 5 years
and 3 years, respectively (Fig. 2h, i). In order to validate
these results, we further conducted immunohistochemis-
try study to investigate SPAG5 protein expression in
PCa. SPAG5 protein expression was increased in PCa
tissues compared with the benign prostate hyperplasia,
and the difference was significant. As shown in Fig. 2j-k,
the SPAG5 positive staining was localized within the
cytoplasm. The analysis indicated weak or no reactivity
in less aggressive PCa but strong staining in the aggres-
sive PCa and CRPC samples.
We investigated the association between SPAG5 pro-
tein expression and clinicopathological variables. As
shown in Additional file 1: Table S1, high SPAG5 expres-
sion was significantly associated with lymph node metas-
tasis, clinical stage, Gleason score, and BCR. We further
identified that the high SPAG5 expression patients had a
shorter overall or BCR-free survival duration compared
to the patients with low SPAG5 expression. We also
identified that SPAG5 was an independent prognostic
variable for BCR-free and overall survival of PCa pa-
tients (Additional file 2: Table S2 and Additional file 3:
Table S3). Collectively, our data showed high SPAG5
protein expression is significantly associated with PCa
progression and poor prognosis.
SPAG5 silence inhibits PCa cell colony formation,
migration, and invasion
To investigate the functional significance of SPAG5
overexpression in PCa, we reduced SPAG5 expression in
PCa cells and studied its impacts on cell colony forma-
tion, migration, and invasion. We employed stable
knockdown strategy targeting SPAG5 in PCa cells. We
identified significant decrease in colony formation in
SPAG5 silence cells relative to control cells (Additional
file 4: Figure S1A). We also identified that SPAG5
silence significantly inhibited PC-3 and LNCaP cell
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migration and invasion (Additional file 4: Figure S1B, C).
We confirmed that SPAG5 protein was significantly re-
duced in SPAG5 silence cells compared with control
cells (Additional file 4: Figure S1D).
SPAG5 is a direct target of miR-539 which may be a
potential anti-progression miRNA
We employed four miRNA target prediction algorithms
provided by miRanda, miRWalk, PICTAR5, and Targets-
can. After integrating the results, we select miR-539 for
further research because of its tumor suppressor
properties in osteosarcoma and thyroid cancer [34, 35].
However, up to now, its roles in PCa and other cancers
are still unclear. We identified that miR-539 is signifi-
cantly decreased in both primary PCa compared with
normal prostate tissues and metastatic PCa relative to
primary PCa tissues (Additional file 5: Figure S2) [30].
The binding site for miR-539 at 3’-UTR of SPAG5 was
depicted (Fig. 3a). We found that co-transfection with
miR-539 can inhibit the luciferase activity when the
construct contained the 3’UTR of SPAG5 (Fig. 3b). Mu-
tation of the binding site can reverse the effects. Taken
Fig. 2 SPAG5 overexpression is associated with PCa progression and poor prognosis. a-d, Box plots showed that SPAG5 was significantly increased in
patients with higher Gleason score relative to patients with lower Gleason score; e, Box plots showed that SPAG5 was significantly increased in patients
with higher grade relative to patients with lower grade; f, g, Box plots showed that SPAG5 mRNA was significantly overexpressed in dead PCa patients
compared with living PCa patients at 3 years and 5 years, respectively; h, i, Box plots showed that SPAG5 mRNA was significantly increased in PCa patients
with BCR compared with PCa patients without BCR at 3 years, and 5 years, respectively. j-l, Immunohistochemical analysis of SPAG5 in, less aggressive PCa
(j), aggressive PCa (h), and CRPC (l)
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together, above results indicated that SPAG5 was a dir-
ect target of miR-539. We further performed qRT-PCR
and western blot to study whether ectopic overexpres-
sion of miR-539 can change SPAG5 expression. We
identified that SPAG5 mRNA expression was signifi-
cantly downregulated in miR-539 transfectants as com-
pared with control cells (Fig. 3c). We also identified that
SPAG5 mRNA expression was inversely associated with
the miR-539 expression level (Fig. 3d). Overall, these re-
sults showed that miR-539 is gradually decreased in PCa
progression and may directly target SPAG5.
miR-539 inhibits PCa cell proliferation, invasion, and
migration by directly targeting SPAG5
We investigated whether miR-539 can change the effects
of SPAG5 on PCa cell colony formation, invasion, and
migration. We found that SPAG5 overexpression can
significantly abrogate the inhibitory effects of PCa cell
colony formation induced by miR-539 (Additional file 4:
Figure S1A). We also found that SPAG5 overexpression
can reverse the inhibitory effects of PCa cell migration
and invasion induced by miR-539 (Additional file 4:
Figure S1B, C). The efficiency of miR-539 upregulation
was studied by western blots (Additional file 4: Figure
S1D). We found that SPAG5 knockdown can result in
similar effects induced by miR-539 upregulation in PCa
cells (Additional file 4: Figure S1).
SPAG5 plays a critical role in PCa growth and metastasis
in vivo
To study the role of SPAG5 on PCa growth and metas-
tasis in vivo, a murine xenograft model using stable
SPAG5 silence PCa cells was employed. SPAG5 silence
can lead to significantly reduced tumor volume and
weight relative to control mice (Fig. 4a-d). SPAG5 si-
lence tumor tissues showed reduced staining for SPAG5
(Fig. 4e-g). SPAG5 silence significantly inhibited PC-3
cell’s ability to metastasize relative to control group
(Fig. 4h). miR-539 upregulation can result in attenuated
metastasis relative to the control group, and lead to
similar results caused by SPAG5 knockdown (Fig. 4). We
did not find any metastases in control or experimental
LNCaP xenografts. Collectively, above data suggested
that SPAG5 may play a critical role in PCa growth and
metastasis in vivo.
Discussion
It is well known that surgery and radiation therapy can
cure the localized PCa [36, 37]. However, many treated
PCa patients will experience local recurrence or metastasis
[2–4]. Metastatic PCa, CRPC, and NEPC are highly resist-
ant to conventional therapy and are at present incurable
[36, 38, 39]. We know that most NEPC patients result
from transdifferentiation of a typical prostate adenocarcin-
oma following androgen-deprivation therapy. We have
Fig. 3 SPAG5 is a direct target of miR-539 in PCa. a, Computational analysis indicating that miR-539 potentially targeted SPAG5. b, Relative luciferase
activities were studied in PCa cells. c, Decrease in SPAG5 mRNA expression by miR-539 was investigated using qRT-PCR. d, Decrease in SPAG5 protein
expression by miR-539 was investigated using western blots. e, SPAG5 mRNA was inversely associated with miR-539 in 180 pairs of PCa tissues
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recently established the first in vivo model of complete
neuroendocrine transdifferentiation using patient-derived
xenografts. Development of therapeutic approaches spe-
cifically targeting metastatic PCa, CRPC, and NEPC asso-
ciated genes may lead to improved PCa management.
Previous study reported overexpression of SPAG5 in sev-
eral types of cancers [9–11]. However, there has been no
report about SPAG5 functional analyses in PCa. In current
study, we try our best to investigate SPAG5 expression
pattern and its association with PCa carcinogenesis,
progression, and prognosis. Our data strongly indicates
that SPAG5 functions as a progression-driving oncogene
in PCa.
We first found a significant upregulation of SPAG5
expression in primary PCa relative to normal prostate
tissues, metastatic PCa relative to primary PCa, CRPC
relative to hormone naïve PCa, and NEPC relative to
prostate adenocarcinoma through microarray analysis,
Fig. 4 SPAG5 plays a critical role in PCa growth and metastasis in vivo. a, b, SPAG5 knockdown in PCa cells significantly inhibits tumor growth in
a mouse xenograft model; c, d, Tumor weights of corresponding mouse xenograft models; e-g, SPAG5 expression analysis was conducted at protein
level by immunohistochemical analysis and western blot. h, SPAG5 played an important role in PCa metastasis in vivo. Ectopic expression of miR-539
can mimic the effects induced by SPAG5 knockdown. All * indicated P value less than 0.05
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indicating SPAG5 may has a critical role in PCa progres-
sion. In order to find the potential critical role of SPAG5
in PCa, we further studied the association of SPAG5
protein staining with clinicopathological variables in
PCa. Results showed that SPAG5 positive staining was
significantly associated with PCa progression. Results
also suggested that positive staining of SPAG5 was inde-
pendently associated with unfavorable outcome of PCa
patients. The prognostic value of SPAG5 was statistically
significant in multivariate analysis adjusted for signifi-
cant variables from univariate analysis, which suggested
SPAG5 expression may be a good molecular marker to
predict PCa prognosis. This is the first direct evidence of
the association between SPAG5 and clinicopathological
variables of PCa and the prognostic role of SPAG5 in
PCa.
In support of our observations in clinical research, we
identified important functional roles of SPAG5 in PCa
cells. Besides the reduction of PCa cell colony formation,
we also found impaired migration and invasion abilities
of PC-3 and LNCaP cells upon inducible shRNA-
mediated SPAG5 silence, indicating that the SPAG5
functioned as a progression associated gene in PCa. We
further confirmed that SPAG5 knockdown can signifi-
cantly inhibit tumor growth and metastasis in vivo. In-
creasing evidence showed miRNAs have critical roles in
several biological processes, including differentiation,
progression, angiogenesis, proliferation, migration, and
invasion. We employed 4 public miRNA target predic-
tion algorithms to identify potential miRNAs which can
regulate SPAG5. Among of these potential miRNAs,
miR-539 attracted our attention due to its tumor sup-
pressor role in osteosarcoma and thyroid cancer [34],
and its unclear roles in PCa and other cancers. The data
from the Taylor et al. study confirmed that miR-539 ex-
pression is low in the more advanced primary PCa, with
the lowest expression in metastatic tissues. We further
identified that miR-539 level was inversely associated
with SPAG5 mRNA level. Our results further confirmed
that the miR-539 can directly target SPAG5. As expect-
edly, ectopic expression of miR-539 can result in similar
results caused by SPAG5 silence in PCa cells. Further-
more, ectopic overexpression of SPAG5 can significantly
reverse the inhibitory effects of miR-539. Taken together,
above results indicated that miR-539 can supress PCa
cell colony formation, migration, and invasion by dir-
ectly targeting SPAG5.
We further investigated the role of SPAG5 on PCa
growth and metastasis in vivo using a murine xenograft
model. We found that SPAG5 knockdown can contrib-
ute to decreased xenograft tumor volume and weight
relative to control group. We also found that SPAG5
knockdown can inhibit PC-3 cell’s ability to metastasize
relative to control group. As expected, miR-539
overexpression can lead to attenuated metastasis relative
to the control group, and lead to similar results induced
by SPAG5 knockdown. Taken together, above results in-
dicated that SPAG5 may play a critical role in PCa
growth and metastasis in vivo.
Conclusions
To our best knowledge, this is the first study to report the
potential progression-driving function of SPAG5 in PCa.
Our study also provides first experimental evidence that
miR-539 can inhibit PCa cell growth and metastasis in
PCa by directly repressing SPAG5. The newly identified
miR-539/SPAG5 signal pathway may provide new insights
into the progression of PCa and a potential therapeutic
target for PCa treatment. Overall, above results indicated
that SPAG5 may play a progression-driving role in PCa
and could serve as a viable therapeutic target.
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